Đang thực hiện thử nghiệm lâm sàng là có khả năng mở rộng đáng kể việc sử dụng y tế của những phân tử này quy định trong vài năm tới. Trong khi một số các ứng dụng điều trị tiềm năng được đánh giá cao như xa trở lại như cuối những năm 1950, ứng dụng trị liệu ban đầu đã được trả lại không thực tế do rất thấp | 208 BIOPHARMACEUTICALS IFN binds its receptor inducing synthesis of eIF-2a protein kinase Invading virus WTO V TOTOTOTO. ỎÔÔĂỔ A ÔÔỎỎỎỎÔỎỎỐÔÔ Cell membrane Cell cytoplasm Figure . Outline of how the eIF-2a protein kinase system promotes an anti-viral effect Ongoing clinical trials are likely to expand considerably the medical uses of these regulatory molecules over the next few years. While at least some of these potential therapeutic applications were appreciated as far back as the late 1950s initial therapeutic application was rendered impractical due to the extremely low THE CYTOKINES THE INTERFERON FAMILY 209 Table . Interferon-based biopharmaceuticals approved to date for general medical use Product Company Indication Intron A rIFN-a-2B Schering Plough Cancer genital warts hepatitis PegIntron A PEGylated rIFN-a-2B Schering Plough Chronic hepatitis C Viraferon rIFN-a-2B Schering Plough Chronic hepatitis B and C ViraferonPeg PEGylated rIFN-a-2B Schering Plough Chronic hepatitis C Roferon A rhIFN-a-2A Hoffman-La-Roche Hairy cell leukaemia Actimmune rhIFN-g-IB Genentech Chronic granulomatous disease Betaferon rIFN-b-1B differs from human Schering AG Multiple sclerosis protein in that Cys 17 is replaced by Ser Betaseron rIFN-b-1B differs from human Berlex Laboratories Relapsing remitting multiple protein in that Cys 17 is replaced by Ser and Chiron sclerosis Avonex rhIFN-b-1A Biogen Relapsing multiple sclerosis Infergen rIFN-a synthetic type I interferon Amgen USA Yamanouchi Europe EU Chronic hepatitis C Rebif rh IFN-b-1A Ares Serono Relapsing remitting multiple sclerosis Rebetron combination of ribavirin and Schering Plough Chronic hepatitis C rhIFN-a-2B Alfatronol rhIFN-a-2B Schering Plough Hepatitis B C and various cancers Virtron rhIFN-a-2B Schering Plough Hepatitis B and C Pegasys PEGinterferon a-2A Hoffman La Roche Hepatitis C Vibragen Omega rFeline interferon-o Virbac Veterinary reduce mortality clinical signs of canine parvovirusis levels at which .
